Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities.
Buti M, Morillas RM, Pérez J, Prieto M, Solà R, Palau A, Diago M, Bonet L, Gallego A, García-Samaniego J, Testillano M, Rodríguez M, Castellano G, Gutiérrez ML, Delgado M, Mas A, Romero-Gómez M, Calleja JL, González-Guirado A, Arenas JI, García-Buey L, Andrade R, Gila A; ORIENTE-2 study group. Buti M, et al. Among authors: bonet l. Eur J Gastroenterol Hepatol. 2015 Jan;27(1):46-54. doi: 10.1097/MEG.0000000000000195. Eur J Gastroenterol Hepatol. 2015. PMID: 25341057
Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
Vispo E, Labarga P, Guardiola JM, Barreiro P, Miralles C, Rubio R, Miralles P, Aguirrebengoa K, Portu J, Morello J, Rodriguez-Novoa S, Soriano V; PERICO Study Group. Vispo E, et al. AIDS Res Hum Retroviruses. 2010 Apr;26(4):419-24. doi: 10.1089/aid.2009.0120. AIDS Res Hum Retroviruses. 2010. PMID: 20377423 Clinical Trial.
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V; PERICO Study Group. Labarga P, et al. J Infect Dis. 2012 Sep 15;206(6):961-8. doi: 10.1093/infdis/jis449. Epub 2012 Jul 17. J Infect Dis. 2012. PMID: 22807523 Clinical Trial.
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
Crespo J, Calleja JL, Fernández I, Sacristan B, Ruiz-Antorán B, Ampuero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M, Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J, Sáez-Royuela F, Arenas J, Rincón D, Prieto M, Jorquera F, Sanchez Ruano JJ, Navascués CA, Molina E, Moya AG, Moreno-Planas JM; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Crespo J, et al. Clin Gastroenterol Hepatol. 2017 Jun;15(6):945-949.e1. doi: 10.1016/j.cgh.2017.02.020. Epub 2017 Feb 24. Clin Gastroenterol Hepatol. 2017. PMID: 28238958
Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.
Lens S, Fernández I, Rodríguez-Tajes S, Hontangas V, Vergara M, Forné M, Calleja JL, Diago M, Llaneras J, Llerena S, Torras X, Sacristán B, Roget M, Fernández-Rodríguez CM, Navascués MC, Fuentes J, Sánchez-Ruano JJ, Simón MÁ, Sáez-Royuela F, Baliellas C, Morillas R, Forns X; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Lens S, et al. Am J Gastroenterol. 2017 Sep;112(9):1400-1409. doi: 10.1038/ajg.2017.157. Epub 2017 Jun 6. Am J Gastroenterol. 2017. PMID: 28585554
Implementing a new HCV model of care for people who use drugs.
Herranz Mochales A, Picchio CA, Nicolàs A, Macià MD, Fernández-Baca MV, Serrano J, Bonet L, Trelles M, Sansó A, Rubí AR, Zamora A, García-Gasalla M, Buti M, Vilella À, Lazarus JV. Herranz Mochales A, et al. Among authors: bonet l. JHEP Rep. 2024 Jun 13;6(10):101145. doi: 10.1016/j.jhepr.2024.101145. eCollection 2024 Oct. JHEP Rep. 2024. PMID: 39308984 Free PMC article.
Cutibacterium Species Valvular and Cardiac Device-Related Infective Endocarditis: Contemporary Data From the GAMES Prospective Cohort (2008-2023).
Alonso-Menchén D, Marín-Arriaza M, Villamarín M, Fernández-Hidalgo N, López-Azor JC, Calderón-Parra J, Águila Fernández-Paniagua E, Hidalgo-Tenorio C, de Alarcón A, Goenaga-Sánchez MÁ, Rodríguez-Esteban MÁ, García Vázquez E, Grillo S, Bouza Santiago E, Muñoz P; Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) Investigators. Alonso-Menchén D, et al. Clin Infect Dis. 2024 Sep 26;79(3):663-671. doi: 10.1093/cid/ciae334. Clin Infect Dis. 2024. PMID: 38913722
Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort.
Calderón-Parra J, Domínguez F, González-Rico C, Arnaiz de Las Revillas F, Goenaga MÁ, Alvarez I, Muñoz P, Alonso D, Rodríguez-García R, Miró JM, De Alarcón A, Antorrena I, Goikoetxea-Agirre J, Moral-Escudero E, Ojeda-Burgos G, Ramos-Martínez A; Spanish Collaboration on Endocarditis (GAMES). Calderón-Parra J, et al. Open Forum Infect Dis. 2024 Mar 13;11(3):ofae121. doi: 10.1093/ofid/ofae121. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38500574 Free PMC article. Clinical Trial.
92 results